Page 5 - Scientific Program Committee News Today

Ad hoc announcement pursuant to Art. 53 LR Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment of adults with insomnia The approval of QUVIVIQ - 25 & 50 mg

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Greenbiz

Radiology Today newsmagazine reaches 40,000 radiology professionals nationwide on a monthly basis, covering areas such as Radiology Management, Bone Densitometry, Mammography, MRI, PACS, CT, Sonography, Nuclear Medicine, Radiation Oncology, Radiation Therapy, contrast agents, and more!

MOUNT ROYAL, NJ (PRWEB) June 03, 2021 -- The American Headache Society®(AHS), a professional society of health care providers dedicated to the study and

BRUKINSA demonstrated superior objective response rate by investigator assessment in the planned interim analysisBRUKINSA was associated with a statistically significant lower risk of atrial fibrillation or flutter Company to host investor call and webcast on Friday, June 11 at noon ETCAMBRIDGE, Mass. & BEIJING--(BU...

(0) SAN FRANCISCO, CA / ACCESSWIRE / May 20, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the highlights of the abstract regarding patient outcomes associated with cancer-related diarrhea ("CRD") by Napo Pharmaceuticals, Inc. ("Napo"), Jaguars wholly owned subsidiary, and Napos collaborators that has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO ®) Annual Meeting, which will be held virtually from June 4-8, 2021...

Jaguar Health and Napo Pharmaceuticals Provide Key Findings from Cancer-related Diarrhea Abstracts Submitted to ASCO for June 2021 Annual Meeting ACCESSWIRE 20 May 2021, 22:43 GMT+10 SAN FRANCISCO, CA / ACCESSWIRE / May 20, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar or the Company) today announced the highlights of the abstract regarding patient outcomes associated with cancer-related diarrhea (CRD) by Napo Pharmaceuticals, Inc. (Napo), Jaguars wholly owned subsidiary, and Napos collabora...

(0) SAN FRANCISCO, CA / ACCESSWIRE / April 29, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced the title of the abstract regarding patient outcomes associated with cancer therapy-related diarrhea ("CTD") by Napo Pharmaceuticals, Inc. ("Napo"), Jaguars wholly owned subsidiary, and Napos collaborators that has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO ®) Annual Meeting, which will be held virtually from June 4-8, 2021. The title of the acce...